Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses an economic analysis and budget impact analysis
Health Canada recently licensed Octaplas, which can now be considered as an alternative to standard fresh frozen plasma (FFP) for certain indications. Since, on average, 200,000 units of FFP are transfused annually in Canada, the widespread implementation of Octaplas may have significant public heal...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2011, March 2011
|
| Series: | CADTH technology report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Health Canada recently licensed Octaplas, which can now be considered as an alternative to standard fresh frozen plasma (FFP) for certain indications. Since, on average, 200,000 units of FFP are transfused annually in Canada, the widespread implementation of Octaplas may have significant public health and economic implications. This study investigates the cost-effectiveness position of Octaplas against standard FFP and its budgetary impact to the health care system |
|---|---|
| Item Description: | Title from PDF title page |
| Physical Description: | 1 PDF file (vii, 27 pages) illustrations |